{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:09:48Z","timestamp":1791234588642,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004951","name":"Atat\u00fcrk \u00dcniversitesi","doi-asserted-by":"publisher","award":["PRJ2017\/10"],"award-info":[{"award-number":["PRJ2017\/10"]}],"id":[{"id":"10.13039\/501100004951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["2214-A"],"award-info":[{"award-number":["2214-A"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["1059B141601251-2214-A"],"award-info":[{"award-number":["1059B141601251-2214-A"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bioorg.2022.105969","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T11:34:13Z","timestamp":1655206453000},"page":"105969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Investigation of carbonic anhydrase inhibitory effects and cytotoxicities of pyrazole-based hybrids carrying hydrazone and zinc-binding benzenesulfonamide pharmacophores"],"prefix":"10.1016","volume":"127","author":[{"given":"Cem","family":"Yamali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Sakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Bandow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Uesawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halise Inci","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bioorg.2022.105969_b0005","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: How to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105969_b0010","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/med.21713","article-title":"Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?","volume":"40","author":"Mishra","year":"2020","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105969_b0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14756360410001689540","article-title":"Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects","volume":"19","author":"Pastorekova","year":"2004","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2022.105969_b0020","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/cmdc.201500596","article-title":"In vivo evaluation of selective carbonic anhydrase inhibitors as potential anticonvulsant agents","volume":"11","author":"Bruno","year":"2016","journal-title":"ChemMedChem"},{"issue":"10","key":"10.1016\/j.bioorg.2022.105969_b0025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/metabo10100412","article-title":"Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment","volume":"10","author":"Angeli","year":"2020","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/oncotarget.422","article-title":"Recent developments in targeting carbonic anhydrase IX for cancer therapeutics","volume":"3","author":"McDonald","year":"2012","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bioorg.2022.105969_b0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/metabo7030048","article-title":"Carbonic anhydrase inhibition and the management of hypoxic tumors","volume":"7","author":"Supuran","year":"2017","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrc2255","article-title":"A microenvironmental model of carcinogenesis","volume":"8","author":"Gatenby","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bioorg.2022.105969_b0045","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.radonc.2013.06.018","article-title":"Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs","volume":"108","author":"Dubois","year":"2013","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105969_b0050","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3892\/or.2015.4184","article-title":"Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation","volume":"34","author":"Duivenvoorden","year":"2015","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105969_b0055","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4149\/neo_2015_054","article-title":"Correlation between carbonic anhydrase IX (CA-9), XII (CA-12) and hypoxia inducible factor-2 alpha (HIF-2 alpha) in breast cancer","volume":"62","author":"Jiang","year":"2015","journal-title":"Neoplasma."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0060","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09553000701616114","article-title":"Hypoxia inducible factor (HIF1 alpha and HIF2 alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy","volume":"84","author":"Koukourakis","year":"2008","journal-title":"Int. J. Radiat. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105969_b0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1359-6349(05)80781-5","article-title":"Hypoxia-inducible factor 1 (HIF-1) and carbonic anhydrase IX (CA 9) expressions in glioblastoma multiform to predict response to radiation therapy. Implication for combined treatment with carbogen and nicotinamide","volume":"3","author":"Simon","year":"2005","journal-title":"Ejc Suppl."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105969_b0070","first-page":"456","article-title":"Clinical value of significance of Hypoxia Inducible Factor-la, Glucose Transporter-1 and Carbonic Anhydrase IX in rectal cancer after preoperative chemoradiotherapy","volume":"24","author":"Vitoratou","year":"2019","journal-title":"J. Buon"},{"issue":"11","key":"10.1016\/j.bioorg.2022.105969_b0075","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.3390\/ijms22116098","article-title":"Inhibition of carbonic anhydrase IX promotes apoptosis through intracellular pH level alterations in cervical cancer cells","volume":"22","author":"Temiz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.bioorg.2022.105969_b0080","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1111\/jcmm.17027","article-title":"Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions","volume":"25","author":"Chen","year":"2021","journal-title":"J. Cell Mol. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105969_b0085","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740338.2014.897328","article-title":"Safety of carbonic anhydrase inhibitors","volume":"13","author":"Swenson","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"issue":"11","key":"10.1016\/j.bioorg.2022.105969_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207417","article-title":"Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: Disconnect between activity and growth inhibition","volume":"13","author":"Mboge","year":"2018","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.bioorg.2022.105969_b0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/1389557521666210831154935","article-title":"Carbohydrazide analogues: a review of synthesis and biological activities","volume":"22","author":"Onyeyilim","year":"2022","journal-title":"Mini Rev. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2022.105969_b0100","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/12081910","article-title":"Biological activities of hydrazone derivatives","volume":"12","author":"Rollas","year":"2007","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bioorg.2022.105969_b0105","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ddr.21329","article-title":"Recent developments of hydrazide\/hydrazone derivatives and their analogs as anticonvulsant agents in animal models","volume":"77","author":"Angelova","year":"2016","journal-title":"Drug Develop. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105969_b0110","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1021\/acs.jmedchem.0c01504","article-title":"New 2-pyrazoline and hydrazone derivatives as potent and selective monoamine oxidase A inhibitors","volume":"64","author":"Salgin-Goksen","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0115","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/14756366.2020.1746783","article-title":"Novel sulindac derivatives: synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity","volume":"35","author":"Bhat","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105969_b0120","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/1573409916666200302120942","article-title":"Synthesis, In silico and in vitro analysis of hydrazones as potential antituberculosis agents","volume":"17","author":"Thorat","year":"2021","journal-title":"Curr. Comput. Aided Drug Des."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105969_b0125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/1570180811310060006","article-title":"Synthesis of Some new 3(2H)-pyridazinone derivatives and evaluation of their analgesic-anti-inflammatory and antimicrobial activities","volume":"10","author":"Sukuroglu","year":"2013","journal-title":"Lett Drug Des Discov."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105969_b0130","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1007\/s00044-012-0253-1","article-title":"Synthesis of some new 2,6-disubstituted-3(2H)-pyridazinone derivatives and investigation of their analgesic, anti-inflammatory and antimicrobial activities","volume":"22","author":"Tiryaki","year":"2013","journal-title":"Med. Chem. Res."},{"issue":"13","key":"10.1016\/j.bioorg.2022.105969_b0135","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.3390\/molecules24132392","article-title":"Synthesis and AChE inhibitory activity of novel thiazolylhydrazone derivatives","volume":"24","author":"Osmaniye","year":"2019","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bioorg.2022.105969_b0140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.pharep.2019.07.006","article-title":"A new series of pyridazinone derivatives as cholinesterases inhibitors: Synthesis, in vitro activity and molecular modeling studies","volume":"71","author":"Ozcelik","year":"2019","journal-title":"Pharmacol. Rep."},{"issue":"18","key":"10.1016\/j.bioorg.2022.105969_b0145","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1016\/j.bmcl.2016.08.006","article-title":"Synthesis of novel hydrazone and azole functionalized pyrazolo[3,4-b]pyridine derivatives as promising anticancer agents","volume":"26","author":"Nagender","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.105969_b0150","doi-asserted-by":"crossref","first-page":"103035","DOI":"10.1016\/j.bioorg.2019.103035","article-title":"Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents","volume":"89","author":"Abbas","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.105969_b0155","doi-asserted-by":"crossref","first-page":"105334","DOI":"10.1016\/j.bioorg.2021.105334","article-title":"Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2","volume":"116","author":"Abou-Seri","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2022.105969_b0160","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/cmdc.202000122","article-title":"Discovery of New Antiproliferative Imidazopyrazole Acylhydrazones Able To Interact with Microtubule Systems","volume":"15","author":"Brullo","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2022.105969_b0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejps.2016.12.011","article-title":"Hydrazone linkages in pH responsive drug delivery systems","volume":"99","author":"Sonawane","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/srep14614","article-title":"Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer","volume":"5","author":"Ye","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2022.105969_b0175","doi-asserted-by":"crossref","first-page":"103658","DOI":"10.1016\/j.bioorg.2020.103658","article-title":"Synthesis and structure-affinity relationship of chlorinated pyrrolidinone-bearing benzenesulfonamides as human carbonic anhydrase inhibitors","volume":"97","author":"Balandis","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2022.105969_b0180","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3390\/ijms20092354","article-title":"Indole-based hydrazones containing a sulfonamide moiety as selective inhibitors of tumor-associated human carbonic anhydrase isoforms IX and XII","volume":"20","author":"Demir-Yazici","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2022.105969_b0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bioorg.2019.01.002","article-title":"Synthesis of novel benzenesulfonamide bearing 1,2,3-triazole linked hydroxy-trifluoromethylpyrazolines and hydrazones as selective carbonic anhydrase isoforms IX and XII inhibitors","volume":"85","author":"Sharma","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.105969_b0190","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejmech.2018.07.054","article-title":"Novel hydrazido benzenesulfonamides-isatin conjugates: Synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies","volume":"157","author":"Abo-Ashour","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105969_b0195","doi-asserted-by":"crossref","first-page":"103222","DOI":"10.1016\/j.bioorg.2019.103222","article-title":"Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors","volume":"92","author":"Yamali","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"27","key":"10.1016\/j.bioorg.2022.105969_b0200","doi-asserted-by":"crossref","first-page":"22917","DOI":"10.1039\/C6RA02168A","article-title":"Design, synthesis and evaluation of benzenesulfonamide-substituted 1, 5-diarylpyrazoles containing phenylacetohydrazide derivatives as COX-1\/COX-2 agents against solid tumors","volume":"6","author":"Lu","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2022.105969_b0205","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bioorg.2018.03.027","article-title":"Anticancer effects of new dibenzenesulfonamides by inducing apoptosis and autophagy pathways and their carbonic anhydrase inhibitory effects on hCA I, hCA II, hCA IX, hCA XII isoenzymes","volume":"78","author":"Gul","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.105969_b0210","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bioorg.2018.01.021","article-title":"New anticancer drug candidates sulfonamides as selective hCA IX or hCA XII inhibitors","volume":"77","author":"Gul","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105969_b0215","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/cbdd.13149","article-title":"Synthesis, molecular modeling, and biological evaluation of 4-[5-aryl-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] benzenesulfonamides toward acetylcholinesterase, carbonic anhydrase I and II enzymes","volume":"91","author":"Yamali","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bioorg.2022.105969_b0220","doi-asserted-by":"crossref","first-page":"113351","DOI":"10.1016\/j.ejmech.2021.113351","article-title":"Comprehensive study on potent and selective carbonic anhydrase inhibitors: Synthesis, bioactivities and molecular modelling studies of 4-(3-(2-arylidenehydrazine-1-carbonyl)-5-(thiophen-2-yl)-1H-pyrazole-1-yl) benzenesulfonamides","volume":"217","author":"Yamali","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105969_b0225","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ph11020054","article-title":"Multidirectional efficacy of biologically active nitro compounds included in medicines","volume":"11","author":"Olender","year":"2018","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11224-020-01612-x","article-title":"Substituent effects of nitro group in cyclic compounds","volume":"32","author":"Jezuita","year":"2021","journal-title":"Struct. Chem."},{"key":"10.1016\/j.bioorg.2022.105969_b0235","doi-asserted-by":"crossref","first-page":"105822","DOI":"10.1016\/j.bioorg.2022.105822","article-title":"Quinazolinone-based benzenesulfonamides with low toxicity and high affinity as monoamine oxidase-A inhibitors: synthesis, biological evaluation and induced-fit docking studies","volume":"124","author":"Yamali","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2022.105969_b0240","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1016\/j.bmc.2008.02.010","article-title":"Nitro as a novel zinc-binding group in the inhibition of carboxypeptidase A","volume":"16","author":"Wang","year":"2008","journal-title":"Bioorgan Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2022.105969_b0245","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1021\/jm800121c","article-title":"Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII","volume":"51","author":"D\u2019Ambrosio","year":"2008","journal-title":"J. Med. Chem."},{"issue":"32","key":"10.1016\/j.bioorg.2022.105969_b0250","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.2174\/138161211798194512","article-title":"A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds","volume":"17","author":"Chung","year":"2011","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105969_b0255","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1021\/acs.jmedchem.8b00147","article-title":"Nitro-Group-Containing Drugs","volume":"62","author":"Nepali","year":"2019","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2022.105969_b0260","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/COC.0000000000000691","article-title":"A Phase 1 Study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors","volume":"43","author":"McDonald","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0265","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14756366.2020.1764549","article-title":"The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells","volume":"35","author":"Peppicelli","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2022.105969_b0270","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.bmc.2017.03.027","article-title":"Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs","volume":"25","author":"Carta","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2022.105969_b0275","doi-asserted-by":"crossref","DOI":"10.2174\/1871520617666170327123909","article-title":"Synthesis and cytotoxic activities of difluoro-dimethoxy chalcones","volume":"17","author":"Yamali","year":"2017","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bioorg.2022.105969_b0280","doi-asserted-by":"crossref","first-page":"105194","DOI":"10.1016\/j.bioorg.2021.105194","article-title":"Exploring of tumor-associated carbonic anhydrase isoenzyme IX and XII inhibitory effects and cytotoxicities of the novel N-aryl-1-(4-sulfamoylphenyl)-5-(thiophen-2-yl)-1H-pyrazole-3-carboxamides","volume":"115","author":"Yamali","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.105969_b0285","unstructured":"H.I. Gul, C. Yamali, Synthesis of pyrazol-benzensulfonamide containing anticancer effective compound having cytotoxic activity, Turk. Pat. Appl. TR 2017006371 A2 20170921 (2017) 1-34."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105969_b0290","doi-asserted-by":"crossref","first-page":"476","DOI":"10.4081\/oncol.2020.476","article-title":"Oral microbiota and oral cancer: Review","volume":"14","author":"Kakabadze","year":"2020","journal-title":"Oncol. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0295","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/ijms22010240","article-title":"Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma","volume":"22","author":"Kitamura","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0300","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"22","key":"10.1016\/j.bioorg.2022.105969_b0305","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.1016\/j.bmcl.2010.09.051","article-title":"Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids","volume":"20","author":"Das","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105969_b0310","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bmcl.2009.12.076","article-title":"3,5-Bis(benzylidene)-1-[4-2-(morpholin-4-yl)ethoxyphenylcarbonyl]-4-piperidone hydrochloride: A lead tumor-specific cytotoxin which induces apoptosis and autophagy","volume":"20","author":"Das","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2022.105969_b0315","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bioorg.2018.12.028","article-title":"Synthesis and bioactivities of pyrazoline benzensulfonamides as carbonic anhydrase and acetylcholinesterase inhibitors with low cytotoxicity","volume":"84","author":"Ozmen Ozgun","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105969_b0320","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2174\/1871520618666180525085445","article-title":"Synthesis and cytotoxicities of new azafluorenones with apoptotic mechanism of action and cell cycle analysis","volume":"18","author":"Gul","year":"2018","journal-title":"Anticancer Agents Med Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105969_b0325","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/14756366.2016.1254207","article-title":"Microwave-assisted synthesis and bioevaluation of new sulfonamides","volume":"32","author":"Gul","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105969_b0330","doi-asserted-by":"crossref","first-page":"103095","DOI":"10.1016\/j.bioorg.2019.103095","article-title":"Synthesis and biological evaluation of some new mono Mannich bases with piperazines as possible anticancer agents and carbonic anhydrase inhibitors","volume":"90","author":"Tugrak","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105969_b0335","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3109\/14756366.2015.1070263","article-title":"Synthesis of mono Mannich bases of 2-(4-hydroxybenzylidene)-2,3-dihydroinden-1-one and evaluation of their cytotoxicities","volume":"31","author":"Tugrak","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2022.105969_b0340","first-page":"5262","article-title":"Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density","volume":"61","author":"Beasley","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2022.105969_b0345","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2017.6829","article-title":"Impact of tumoral carbonic anhydrase IX and Ki-67 expression on survival in oral squamous cell carcinoma patients","author":"Brockton","year":"2017","journal-title":"Oncol Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105969_b0350","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.oraloncology.2011.11.015","article-title":"Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis","volume":"48","author":"Chien","year":"2012","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105969_b0355","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/ijms20020375","article-title":"Investigation of the prognostic role of carbonic anhydrase 9 (CAIX) of the cellular mRNA\/Protein level or soluble CAIX protein in patients with oral squamous cell carcinoma","volume":"20","author":"Eckert","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105969_b0360","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1007\/s13277-015-3692-8","article-title":"Carbonic anhydrase IX overexpression regulates the migration and progression in oral squamous cell carcinoma","volume":"36","author":"Yang","year":"2015","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2022.105969_b0365","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3390\/ijms23052601","article-title":"Tumor-specificity, neurotoxicity, and possible involvement of the nuclear receptor response pathway of 4,6,8-trimethyl azulene amide derivatives","volume":"23","author":"Naitoh","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822003741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822003741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:55:27Z","timestamp":1777463727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822003741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":73,"alternative-id":["S0045206822003741"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.105969","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of carbonic anhydrase inhibitory effects and cytotoxicities of pyrazole-based hybrids carrying hydrazone and zinc-binding benzenesulfonamide pharmacophores","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.105969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105969"}}